Les Laboratoires SERVIER

Type: Company
Name: Les Laboratoires SERVIER
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Brussels GA&P (July 2014)

NewsAntitrustThe Spanish competition authority fines several fire extinguishing equipment manufacturers over EUR 2 million for operating a cartel.The Spanish Comisión Nacional de los Mercados y la Competencia (CNMC) has imposed a 2.13 million EUR fine ... [Published Lexology - Jul 30 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Xention Awarded £1.4M From Technology Strategy Board To Develop New Medicines For Atrial Fibrillation

The Technology Strategy Board, the UK’s innovation agency, will co-fund the preclinical development of Xention’s novel inhibitors of the cardiac potassium channel, IKAChXENTION LTD ("Xention"), the Cambridge-based biopharmaceutical company specialising ... [Published Pharmaceutical Online - Jul 29 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Cellectis to Sell Stem Cell Subsidiary

Cellectis , a developer of cancer immunotherapies based on its engineered allogenic Chimeric Antigen Receptor T-cell (CAR-T) platform, said today it will get out of the stem cell business sell its Swedish subsidiary Cellectis AB to Takara Bio. The price ... [Published Genetic Engineering News - Jul 29 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Xention awarded $2.4M from Technology Strategy Board to develop new medicines for atrial fibrillation

CAMBRIDGE, U.K.—Xention Ltd., a Cambridge-based biopharmaceutical company specializing in the discovery and development of ion channel-modulating drugs, announced today that it had secured £1.4 million co-funding (approximately $2.4 million) from the ... [Published Drug Discovery News - Jul 25 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

BioInvent swings to profit in Q2 2014

BioInvent International AB (STO:BINV.ST), a research-based pharmaceutical company, on Thursday reported earnings after tax of SEK3.7m, or diluted EPS of SEK0.04. for the second quarter of 2014, from April 2014 to June 2014. This was an improvement over ... [Published Individual.com - Jul 25 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 2 reports

Drugmaker Servier fined €330 million for blocking generic competition

the European Commission announced that the French pharmaceutical company Servier, and five other drugmakers (Niche, Matrix, Teva, Krka and Lupin) have been fined a total of €427.7 million by the European Commission. The fines were imposed after a series ... [Published Lexology - Jul 18 2014]
First reported Jul 14 2014 - Updated Jul 15 2014 - 2 reports

EC imposes $580 million fine for alleged actions to prevent or delay generic entry

, the antitrust watchdog of the 28-member-state European Union imposed fines totaling €427.7 million (US$ 580 million) on French pharmaceutical company Servier and five generic drug manufacturers based on Servier’s acquisition of alternative technologies ... [Published Lexology - Jul 15 2014]
First reported Jul 10 2014 - Updated Jul 11 2014 - 4 reports

Lupin, Unichem Unit To Appeal EU Fine For Collusion With Servier

Article # 28140711002Posted: Jul. 10, 2014 10:15 PM GMTExecutive SummaryLupin and Unichem Laboratories said they would appeal million-dollar fines levied by the European Union's Competition Commission, which said they and three other generics makers colluded ... [Published Health News Daily - Jul 11 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 3 reports

Generic drug makers to challenge EU anti-trust fine

EU’s Competion Commission had found the firms guilty of an alleged settlement agreement with a French drug maker to delay the launch of a copy of hypertension drug Perindopril. Photo: MintMumbai: Three generic drug makers, including India’s Lupin Ltd ... [Published Livemint.com - Jul 10 2014]
First reported Jul 09 2014 - Updated Jul 10 2014 - 2 reports

Lupin, Unichem To Share $580 Million EC Collusion Fine With Servier

Article # 28140710007Posted: Jul. 10, 2014 7:35 AM GMTExecutive SummaryIndia drug makers Lupin and Unichem were fined a share of $580 million by the European Commission for engaging with France's Servier in plan to delay the arrival of generics of its ... [Published Health News Daily - Jul 10 2014]
First reported Jul 09 2014 - Updated Jul 10 2014 - 25 reports

EU fines Teva for generic blood pressure treatment delay

The EU charges that the French company Servier systematically bought out competitive threats through payments to Teva and the other companies not to launch generic Perindropil.Teva denies any wrongdoing. “We stand by our belief that Teva did not engage ... [Published Globes - Jul 10 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 3 reports

BioInvent Has Received Milestones From Bayer Pharma S.A. And Servier

7/7/2014 11:57:11 AMLUND, Sweden--(BUSINESS WIRE)--Regulatory News:BioInvent (STO:BINV)BioInvent International (OMXS: BINV) today announced that it has received two separate milestone payments, together worth 1 MEuro, as a result of milestones being reached ... [Published BioSpace - Jul 07 2014]

Quotes

Tim Brears, CEO of Xention said: "We are delighted to have succeeded in this competitive process and that the Technology Strategy Board has recognized not only the quality of our programme but also the promise IKACh represents as a new target for AF alongside IKur, both of which are key atrial-selective cardiac ion channels"
...for which patients remain underserved despite recent advances in therapies," said Scott Koenig, M D , Ph D , President and CEO of MacroGenics. "We look forward to initiating the Phase 1 study of MGD007, our second DART candidate to enter the clinic, in the second half of 2014."
...ability to redirect T cells against CD123-positive leukemic blasts in patients with relapsed or refractory AML," and in addition he stressed that "the development of new immune-based therapies from MacroGenics DART platform not only reinforces, but also diversifies Servier's R&D oncology portfolio."
..." The sources defined Landa's behavior as "a settling of personal accounts appropriate to a backwoods swamp, not a global company" and accused him of behaving callously, disrespectfully, and discreditably

More Content

All (158) | News (133) | Reports (0) | Blogs (15) | Audio/Video (0) | Fact Sheets (2) | Press Releases (7)
sort by: Date | Relevance
Cellectis Sells Swedish Subsidiary Cellectis AB... [Published Bioresearch Online - 12 hours ago]
3 Biotech Catalyst Stocks To Own [Published Seeking Alpha - 19 hours ago]
Takara Bio to acquire Cellectis from Cellectis [Published Individual.com - Jul 30 2014]
XOMA to Announce Second Quarter 2014 Financial ... [Published Scottrade - Jul 30 2014]
Cellectis sells Swedish subsidiary to Japan’s T... [Published Pharma Letter - Jul 30 2014]
Brussels GA&P (July 2014) [Published Lexology - Jul 30 2014]
Xention Awarded £1.4M From Technology Strategy ... [Published Pharmaceutical Online - Jul 29 2014]
Cellectis to Sell Stem Cell Subsidiary [Published Genetic Engineering News - Jul 29 2014]
How Your Diet Affects Your Mental Health [Published Lifehacker Australia - Jul 27 2014]
Xention awarded $2.4M from Technology Strategy ... [Published Drug Discovery News - Jul 25 2014]
Just what the doctor ordered [Published Hindu Business Line - Jul 25 2014]
BioInvent swings to profit in Q2 2014 [Published Individual.com - Jul 25 2014]
CLSN's Dignity At Work, GSK's Flonase To Go OTC... [Published RTTNews.com - Jul 25 2014]
MacroGenics' DART Candidate IND for Colorectal ... [Published GlobeNewswire: Acquisitions News - Jul 24 2014]
MacroGenics' DART Candidate IND for Colorectal ... [Published EMoneyDaily - Jul 24 2014]
MacroGenics' DART Candidate IND for Colorectal ... [Published BusinessWeek - Jul 24 2014]
Xention awarded £1.4m from Technology Strategy ... [Published European Pharmaceutical Manufacturer - Jul 24 2014]
A Bad Diet Could Contribute To Bad Mental Health [Published Business Insider - Jul 24 2014]
New Market Research Report: Chronic Heart Failu... [Published Digital Journal - Jul 23 2014]
MacroGenics doses first patient in Phase I AML ... [Published Individual.com - Jul 22 2014]
You are what you eat: how diet affects mental w... [Published Conversation AU - Jul 22 2014]
Hungary’s Govt To Sign Strategic Agreements Wit... [Published XpatLoop.com - Jul 21 2014]
Pharmaceutical manufacturers are fined and may ... [Published Lexology - Jul 19 2014]
Focus on regulatory law - July 2014 [Published Lexology - Jul 18 2014]
Drugmaker Servier fined €330 million for blocki... [Published Lexology - Jul 18 2014]
European Commission fines Servier and five gene... [Published Matthew Arnold & Baldwin LLP - Jul 18 2014]
Advisory firm backs Teva board candidates [Published Globes - Jul 17 2014]
Competition law cases in the lifesciences secto... [Published Lexology - Jul 17 2014]
Benefit of vorapaxar may be greater with BMS th... [Published Orthopedics Today - Jul 16 2014]
Unichem Labs' net dips by 16% in Q1 [Published PharmaBiz - Jul 16 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Frontrunning: July 10 [Published Zero Hedge - Jul 10 2014]
Espirito Santo Financial Suspends Shares, Bonds on ESI Exposure ( BBG ) Europe Stocks Drop for Fifth Day as Espirito Santo Sinks ( BBG ) Espirito Santo Creditors Doubt Containment on Missed Payment ( BBG ) French Stocks Seen Extending Losses on Economy ...
Servier distort competition [Published PharmaGossip - Jul 09 2014]
BRUSSELS — The European Union's antitrust body is imposing a fine of 428 million euros ($580 million) on France's pharmaceutical company Servier and five producers of generic medicines for distorting competition. The 28-nation bloc's executive Commission ...
BioInvent Has Received Milestones from Bayer an... [Published Business Wire Science: Science News - Jul 07 2014]
LUND, Sweden--(BUSINESS WIRE)--Regulatory News: BioInvent (STO:BINV) BioInvent International (OMXS: BINV) today announced that it has received two separate milestone payments, together worth 1 MEuro, as a result of milestones being reached under collaborations ...
BioInvent Has Received Milestones from Bayer an... [Published Business Wire Health News - Jul 07 2014]
LUND, Sweden--(BUSINESS WIRE)--Regulatory News: BioInvent (STO:BINV) BioInvent International (OMXS: BINV) today announced that it has received two separate milestone payments, together worth 1 MEuro, as a result of milestones being reached under collaborations ...
Tea Party Rally Won't Include Alexander's Tea P... [Published Breitbart Feed - Jun 24 2014]
A rally scheduled for Thursday night has all the makings of a political boon to Tennessee State Sen. Joe Carr, who's challenging Sen. Lamar Alexander (R-TN) in the Senate primary. Stars of the Tea Party, including former Alaska Gov. Sarah Palin, ...
1 2 3

Press Releases

sort by: Date | Relevance
MacroGenics' DART Candidate IND for Colorectal ... [Published GlobeNewswire: Acquisitions News - Jul 24 2014]
Galapagos receives EU2 million from osteoarthri... [Published GlobeNewswire: Acquisitions News - Mar 07 2014]
Celladon Announces Option Agreement With Servier [Published GlobeNewswire: Acquisitions News - Feb 24 2014]
MacroGenics Achieves Milestone as Servier Exerc... [Published GlobeNewswire: Acquisitions News - Feb 05 2014]
Avalancha de fracturas de caderas afectará a As... [Published PR Newswire - Dec 12 2013]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.